Phathom Pharmaceuticals Inc

NASDAQ:PHATUnited States

Phathom Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The Company’s pipeline product candidate, VOQUEZNA, VOQUEZNA TRIPLE PAK, and VOQUEZNA DUAL PAK. Its product candidate, VOQUEZNA, contains vonoprazan, an oral small molecule potassium-competitive acid blocker (PCAB). PCABs are a novel class of medicines that block acid secretion in the stomach. Vonoprazan has also demonstrated clinical benefits in the treatment of erosive gastroesophageal reflux disease (erosive GERD), and in combination with antibiotics for the treatment of Helicobacter pylori (H. pylori) infection. GERD and H. pylori infection are two of the most common acid-related GI diseases. GERD is a disease that develops when the reflux of acidic stomach contents causes troublesome symptoms and/or complications. H. pylori is a bacterial pathogen.

Contact Information

Headquarters

100 Campus Drive, Suite 102FLORHAM PARK, NJ, United States 07932

Phone

302-636-5400

Fax

302-636-5454

Executives

Independent Chairman of the Board

Michael Cola

President, Chief Executive Officer, Director

Terrie Curran

Co-Founder, Chief Operating Officer

Azmi Nabulsi

Co-Founder, Director

David Socks

Chief Financial Officer and Business Officer

Molly Henderson